- Home
- CMMB vs ENGS Comparison
CMMB vs ENGS Comparison
Compare CMMB & ENGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMMB
- ENGS
- Stock Information
- Founded
- CMMB 2004
- ENGS 1998
- Country
- CMMB Israel
- ENGS United Kingdom
- Employees
- CMMB N/A
- ENGS N/A
- Industry
- CMMB Biotechnology: Pharmaceutical Preparations
- ENGS
- Sector
- CMMB Health Care
- ENGS
- Exchange
- CMMB Nasdaq
- ENGS NYSE
- Market Cap
- CMMB 23.0M
- ENGS 23.8M
- IPO Year
- CMMB N/A
- ENGS 2025
- Fundamental
- Price
- CMMB $1.19
- ENGS $1.67
- Analyst Decision
- CMMB Strong Buy
- ENGS
- Analyst Count
- CMMB 2
- ENGS 0
- Target Price
- CMMB $8.50
- ENGS N/A
- AVG Volume (30 Days)
- CMMB 211.9K
- ENGS 460.6K
- Earning Date
- CMMB 08-20-2025
- ENGS 01-01-0001
- Dividend Yield
- CMMB N/A
- ENGS N/A
- EPS Growth
- CMMB N/A
- ENGS N/A
- EPS
- CMMB N/A
- ENGS N/A
- Revenue
- CMMB N/A
- ENGS $11,089,930.00
- Revenue This Year
- CMMB N/A
- ENGS N/A
- Revenue Next Year
- CMMB N/A
- ENGS N/A
- P/E Ratio
- CMMB N/A
- ENGS N/A
- Revenue Growth
- CMMB N/A
- ENGS 6.58
- 52 Week Low
- CMMB $0.87
- ENGS $1.36
- 52 Week High
- CMMB $2.55
- ENGS $10.24
- Technical
- Relative Strength Index (RSI)
- CMMB 40.31
- ENGS N/A
- Support Level
- CMMB $1.17
- ENGS N/A
- Resistance Level
- CMMB $1.24
- ENGS N/A
- Average True Range (ATR)
- CMMB 0.07
- ENGS 0.00
- MACD
- CMMB -0.01
- ENGS 0.00
- Stochastic Oscillator
- CMMB 34.67
- ENGS 0.00
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.
About ENGS ENERGYS GROUP LTD
Energys Group Ltd provides end-to-end customized solutions and services involving the retrofitting of existing infrastructure to reduce their CO2 emissions. The Company's customers include large national account end-users, including universities, schools, hospitals and electrical distributors in the United Kingdom.